BHCM
IGMS

Brevan Howard Capital Management’s IGM Biosciences IGMS Stock Holding History

Brevan Howard Capital Management’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,589
Closed -$102K – 1201
2024
Q1 		$102K Sell
10,589
-1,288
-11% -$14.9K ﹤0.01% 890
2023
Q4 		$98.7K Buy
+11,877
New +$69K ﹤0.01% 959

Other funds holding IGMS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Brevan Howard Capital Management's IGMS Position: Q2 2024 in Review

Brevan Howard Capital Management sold out of IGM Biosciences (IGMS) in Q2 2024, closing a stake of 10,589 shares — an estimated $102K sold.

Brevan Howard Capital Management first reported a position in IGMS in Q4 2023 and held it in 2 quarters. The position peaked at $102K in Q1 2024. 82 funds tracked by Wall St. Rank hold IGMS as of Q2 2024.

  • Brevan Howard Capital Management reported no remaining IGM Biosciences position as of Q2 2024 after selling out during the quarter.
  • Brevan Howard Capital Management sold 10,589 IGM Biosciences shares in Q2 2024, an estimated $102K.
  • Brevan Howard Capital Management first reported a position in IGM Biosciences in Q4 2023 and held it in 2 quarters.
  • Brevan Howard Capital Management's IGM Biosciences position peaked at $102K in Q1 2024.
  • 82 funds tracked by Wall St. Rank held IGM Biosciences as of Q2 2024.

Based on Brevan Howard Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.